Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, this improvement lasted for up to 140 days after the single dose.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a proof-of-concept study with a single application of the anti-IL-33 antibody etokimab (ANB020) in 12 patients with moderate or severe AD, 33% of patients reached the primary end point EASI75 and 83% reached EASI50 (ref.68).”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Etokimab inhibited direct, as well as CXCR1-dependent, neutrophil migration in vitro.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Self-citationA role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska-Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 979 · cited 1×
“The IL-33/ST2 pathway contributes to inflammation associated with disorders including atopic dermatitis (AD) (7), asthma (8), inflammatory bowel disease (9), and arthritis (10, 11).”
BackgroundSelf-citationγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation
Kim, B. S., Siracusa, M. C., Saenz, S. A., Noti, M., Monticelli, L. A., Sonnenberg, G. F., Hepworth, M. R., Van Voorhees, A. S., Comeau, M. R., & Artis, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005374 · Cited by 731 · cited 1×
“In murine models, either IL-33 or TSLP alone is sufficient to promote the development of AD-like inflammation (39).”
BackgroundSilverberg, J. I., & Hanifin, J. M. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.031 · Cited by 604
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G
Lefrançais, E., Roga, S., Gautier, V., Gonzalez-de-Peredo, A., Monsarrat, B., Girard, J.-P., & Cayrol, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115884109 · Cited by 594 · cited 1×
“Furthermore, IL-33 can be cleaved into active forms by neutrophil elastase and cathepsin G (21), implicating an inflammatory cycle.”
BackgroundThaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Soluble ST2 Blocks Interleukin-33 Signaling in Allergic Airway Inflammation
Hayakawa, H., Hayakawa, M., Kume, A., & Tominaga, S.-I. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704916200 · Cited by 546 · cited 1×
“The soluble IL-33 decoy receptor soluble ST2 (sST2) has been used in treating allergic diseases in model systems (27).”
Cited by
Items 201–259 of 259
Zhang, F., Wu, J., Li, Z., Gan, L., Cao, H., Chen, C., Sun, Z., Zhang, J., Li, H., Zhang, X., et al. (2026) · Inflammation · doi:10.1007/s10753-025-02364-8 · Cited by 3
“Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in atopic dermatitis and peanut allergy [39, 40].”
Liu, W., Zhang, H., Chen, X., Xiao, Y., & Su, J. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09127-1 · Cited by 3
Danto, S. I., Tsamandouras, N., Reddy, P., Gilbert, S. A., Mancuso, J. Y., Page, K. M., BEEBE, J. S., Peeva, E., & Vincent, M. S. (2024) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00894-8 · Cited by 3
“…benefit most The modest aggregate clinical effects seen in the current study with PF-06817024 are consistent with results from clinical trials with other IL-33 inhibitors such as itepekimab and etokimab; however, these trials were conducted in patients with asthma and AD, respectively [28, 32].”
ResultBiologics in atopic dermatitis
Chan, S. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000740 · Cited by 3
Zylstra, J., Partridge, M. A. K., & Sumner, G. (2021) · Bioanalysis · doi:10.4155/bio-2021-0172 · Cited by 4
Serum levels and single nucleotide polymorphisms of the interleukin-33 gene in atopic dermatitis
Zaryczańska, A., Gleń, J., Zabłotna, M., Nowicki, R. J., & Trzeciak, M. (2022) · Advances in Dermatology and Allergology · doi:10.5114/ada.2022.113130 · Cited by 4
“The study was conducted in 2012-2019, however we find it particularly significant in 2021 in the light of ongoing studies on etokimab and in the beginning of the era of biologic treatment in AD [8].”
BackgroundEmerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials
Obed, O., Chong, A. C., Su, M., & Ong, P. Y. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2345643 · Cited by 5
“Etokimab (ANB020) is an anti-IL-33 monoclonal antibody [60].”
Lu, G., & Cui, G. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251344049 · Cited by 2
Heul, A. V., & Kim, B. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.06.005 · Cited by 2
Zhang, Y., Wu, Y., Wang, Y., & Zhou, H. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157101 · Cited by 3
Ranjbar, M., Whetstone, C. E., Hansi, R. K., Sadeghi, F., & Gauvreau, G. M. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2619605 · Cited by 3
“Negative Phase 2b results in the atopic dermatitis ATLAS study led to discontinuation of etokimab [101,102].”
Kishimoto, M., Deshpande, G. A., Fukui, S., Komagata, Y., Ohyama, M., & Kaname, S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2149494 · Cited by 2
“Systemic drugs, including lebrikizumab and tralokinumab (anti-IL-13) [33–35], fezakinumab (anti-IL-22) [36], etokimab (anti-IL-33) [37], nemolizumab (anti-IL-31Rα) [38,39] and tezepelumab (anti-thymic stromal lymphopoietin (TSLP)) [40,41] have been assessed for efficacy in AD in phase II and phase III trials.”
BackgroundObata‐Ninomiya, K., Tharmalingam, J., & Ziegler, S. F. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.70020 · Cited by 2
Ge, Y., Janson, V., Dong, Z., & Liu, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189296 · Cited by 4
Biologics in Treatment for Chronic Rhinosinusitis with Comorbid Asthma
Xu, Y., Bi, M., Tan, K. S., Mi, J., & Hong, H. (2021) · Current Treatment Options in Allergy · doi:10.1007/s40521-021-00282-2 · Cited by 2
Lehman, H. K., & Sabella, C. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00039-4 · Cited by 2
Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy
Kumar, P., Ashawat, M. S., Kumar, A., Guleria, A. S., & Thakur, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010311098240530104530 · Cited by 2
Sahara, S., Ueno, A., Wakita, N., Iwai, M., Uda, J., Nakaoji, K., Hamada, K., Maeda, A., Kaneda, Y., & Fujimoto, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302781 · Cited by 1
“Currently, biologics targeting TSLP and IL-33 are being developed and are considered promising therapeutic agents for AD [46, 47].”
BackgroundEngineered strategies for the allergic disease therapy
Tian, Y., Wu, X., Sun, X., Rong, L., & Han, K. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240115 · Cited by 1
From neuroimmune circuits to targeted therapy of chronic pruritus
Ramcke, T., & Kaplan, D. H. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100121 · Cited by 2
“Phase 2 clinical trials explored the therapeutic benefit of IL-33 neutralization (etokimab) 275 and ST2-receptor blockade (astegolimab) 276 in AD.”
The Role of and Therapeutic Strategies for Eosinophils in Atopic Dermatitis
Cheng, G., Sun, S., Deng, G., Luo, Y., Li, M., Zhao, H., Yang, X., Wang, R. L., Kuai, L., Zhang, Y., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14061212 · Cited by 1
“For instance, a clinical trial found that treatment with the anti-IL-33 antibody etokimab significantly decreased both peripheral blood eosinophil counts and EASI scores in AD patients [101,102].”
Advances in targeting IL-1 family cytokines for the treatment of inflammatory diseases
Gabay, C., Girard-Guyonvarc’h, C., Vaillant, L., & Jarlborg, M. (2026) · Nature Reviews Rheumatology · doi:10.1038/s41584-026-01395-1 · Cited by 2
“Etokimab, a monoclonal anti-IL-33 antibody, showed fast and sustained clinical benefits in a small clinical trial that involved 12 adults with atopic dermatitis 125 .”
Nowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2020.102084 · Cited by 2
Nowicki, R. J., Trzeciak, M., Rudnicka, L., Szepietowski, J. C., Kulus, M., Kupczyk, M., Mastalerz–Migas, A., Peregud-Pogorzelski, J. W., Jahnz‐Różyk, K., Narbutt, J., et al. (2020) · Dermatology Review · doi:10.5114/dr.2020.101669 · Cited by 1
Biologics in severe asthma – a molecular perspective
Haidar, L., & Panaitescu, C. B. (2022) · Alergologia · doi:10.26416/aler.6.1.2022.6274 · Cited by 1
Association between IL-25, IL-33 and atopic dermatitis: A systematic review and meta-analysis
Zhou, B., Yue, X., Liang, S., Shang, S., Xiang, L., Zhou, K., & Li, L. (2023) · European Journal of Inflammation · doi:10.1177/1721727x231183670 · Cited by 1
“36 Currently, there is no anti-IL-25 antibody approved for use clinically.”
BackgroundDuca, E., & Pop, T. L. (2021) · Pediatru ro · doi:10.26416/pedi.64.4.2021.5782
Resende, R., de Oliveira, V. J., Correa, A. S., de Araújo, P. T., & Taketomi, E. A. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2027758
“lymphopoietin (TSLP), lebrikizumab - anti-IL-13, and etokimab - anti-IL-33 are the newest promising immunobiologics, particularly in those patients that have clear evidence of proteaseactivated epithelial cell [63,64].”
BackgroundThe new and old: Atopic dermatitis biologics
Logas, C. M., Glick, B. P., & Rosso, J. Q. D. (2022) · Dermatological Reviews · doi:10.1002/der2.105
Васильевич, K. В. (2022) · Springer eBooks · doi:10.1007/978-3-031-04309-3_5
Measuring the level of IL-4 and IL-25 in the serum of eczema patients
Mohammed, A., & Najm, A. A. (2023) · Romanian Journal of Infectious Diseases · doi:10.37897/rjid.2023.3.2
“The society works to create a mixture of genetic and hormonal factors and does not depend on sex alone [29].”
BackgroundBiologics in the Management of Sever Atopic Dermatitis
Abadie, M. A., Sharara, Z., & Al Abadie, S. (2023) · International Journal of Clinical & Experimental Dermatology · doi:10.33140/ijced.08.02.05
Eosinophilic esophagitis: Immune response
Gabryszewski, S. J., Muir, A. B., & Cianferoni, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96018-2.00178-4
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2023) · Figshare · doi:10.6084/m9.figshare.24257422
Autoimmune pancreatitis type 1 and type 2: what we know so far
Piotrowska, M., Gmitrzuk, J., Malinka, Z., Wiśniewska, K., Jachymek, A., Opatowska, M., Jakubiec, J., & Kucharski, T. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52733
“The therapeutic implications of etokimab were presented in atopic dermatitis and its promising potential in autoimmune diseases was suggested 36 .”
BackgroundMast Cells in Allergy, Host Defense and Immune Regulation
Marshall, J. S., Nanjundappa, R. H., Barra, J., Portales‐Cervantes, L., & Haidl, I. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00190-3
Biologics in the Treatment of Atopic Dermatitis
Sharara, Z. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1013012 · Cited by 1
Danto, S. I., Tsamandouras, N., Reddy, P., Gilbert, S. A., Mancuso, J. Y., Page, K. M., BEEBE, J. S., Peeva, E., & Vincent, M. S. (2024) · Figshare · doi:10.6084/m9.figshare.26944443
Danto, S. I., Tsamandouras, N., Reddy, P., Gilbert, S. A., Mancuso, J. Y., Page, K. M., BEEBE, J. S., Peeva, E., & Vincent, M. S. (2024) · Figshare · doi:10.6084/m9.figshare.26944440
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26623558
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.24257639
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26623561
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26623570
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26623564
Gao, J., Li, Y., Guan, X., Mohammed, Z., Gomez, G., Hui, Y. Y., Zhao, D., Oskeritzian, C. A., & Huang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26623567
Cytokine in itch induction and modulation
Tseng, P., & Hoon, M. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34172-4.00006-9
Price, E., Whetstone, C. E., Al‐Sajee, D., Alsaji, N., Howie, K. J., Munoz, C. E., Sehmi, R., Lima, H. C., & Gauvreau, G. M. (2026) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2026.100696
Okada, S., Lee, P. Y., Yasudo, H., Ohnishi, Y., Son, M. B. F., Newburger, J. W., & Hasegawa, S. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2655165
“Etokimab, a humanized IgG1 monoclonal antibody, consistently demonstrated rapid and sustained clinical improvement in phase 2a trials of adults with moderate-to-severe AD or peanut allergy [127,128].”
Anti -IL-4, -IL-13 and -IgE vaccination for the treatment of allergic diseases
Conde, E. (2020) · theses.fr (ABES) · doi:10.70675/595ec855zeea2z4557z95b5z4de5bf043ffd
Atopic Dermatitis: New Targets and Emerging Systemic Therapies
Avallone, G., Beaziz, J., Margiotta, F. M., Langer, K., DUCA, E. D., & Guttman‐Yassky, E. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01054-x
“In contrast, targeting IL-33 with a single IV 300-mg dose of etokimab in a phase IIa proof-of-concept study (NCT03533751) led to rapid clinical improvement, with EASI-75 achieved in 61% of treated adult patients within 4 weeks, while IGA 0/1 was achieved only in 25% of patients [146].”
Therapeutic monoclonal antibodies in allergy: current landscape and future directions
Renaudineau, Y., & Brooks, W. H. (2026) · Journal of Allergy and Hypersensitivity Diseases · doi:10.1016/j.jahd.2026.100070
Liao, R., & Yin, H. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579035
Mu, S., Wang, Y., Qin, W., Mao, M., Wang, Y., Zhang, Y., & Wang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864351
“IL-33 is involved in epithelial alarmin signaling and type 2 in fl ammation, but early clinical evaluation has primarily been conducted in adults with AD, and pediatric evidence remains lacking (90, 91).”
Li, Z., Ke, X., Yang, X., Zhu, W., Gu, X., & Chen, W. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116336
Dermatite atopica moderata-grave: quali novità per il pediatra
Andrenacci, B., Cipriani, F., Combierati, P., Gragnoli, B., Maiello, N., Ricci, G., Ruggiero, G., & Galli, E. (2023) · Italian Journal of Pediatric Allergy and Immunology · Cited by 1
Li, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1970480
Beyond the Alarmin: Nuclear Interleukin-33 and Skin Barrier Dysfunction in Atopic Dermatitis
Muto, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207781
“In a phase IIa study on 12 adults with moderate-to-severe AD, a single dose of the anti-IL-33 antibody etokimab produced rapid clinical benefits, with 83% of patients achieving a 50% reduction in the Eczema Area and Severity Index and a decrease in peripheral eosinophil levels [40].”
Understanding the roles of interleukin-33: is there promise for therapeutic targeting?
Gao, X., Yu, Y., Zhong, S., Zhang, W., & Dong, L. H. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2755129
Metadata
- Authors
- Chen, Y.-L., Gutowska-Owsiak, D., Hardman, C. S., Westmoreland, M., MacKenzie, T., Cifuentes, L., Waithe, D., Lloyd-Lavery, A., Marquette, A., Londei, M., & Ogg, G.
- Affiliations
- University of Oxford (GB)
- MRC Human Immunology Unit, NIHR Biomedical Research Centre, Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
- AnaptysBio, Inc. (United States) (US)
- Corresponding author
- Ogg, Graham
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-10-23
- Volume
- 11
- Issue
- 515
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2979421310
- Cited by
- 250
- References
- 46
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 38 · 2023: 31 · 2022: 48 · 2021: 50 · 2020: 37 · 2019: 1
- FWCI
- 34.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council (MCUU_0008/5)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, neutrophil migration, CXCR1, interleukin-8, eosinophils, skin inflammation, Eczema Area and Severity Index
- MeSH terms
- Interleukin-33, Antibodies, Monoclonal, Cell Movement, Dermatitis, Atopic, Eczema, Humans, Inflammation, Neutrophils, Skin, Interleukin-12, Receptors, Interleukin-8A, Extracellular Fluid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.